Mevalonate Metabolism in Cancer Stemness and Trained Immunity.

Mevalonate Metabolism in Cancer Stemness and Trained Immunity.
复制标题

DOI:
10.3389/fonc.2018.00394
复制
发表时间:
2018
影响因子:
4.7
通讯作者:
Thurnher M
Thurnher M
中科院分区:
医学3区
文献类型:
--
作者:
Gruenbacher G;Thurnher M

文献摘要

参考文献

被引文献

相似文献

甲羟戊酸代谢为癌症和免疫细胞提供了多种产物,以确保细胞功能。将甲羟戊酸代谢提高到更高水平的类似代谢重编程似乎驱动癌细胞的上皮间充质转化(EMT)(产生具有干细胞特性的癌细胞的逆分化程序)和免疫细胞训练以增加对二次刺激的响应性。在这篇综述中,我们讨论了甲羟戊酸代谢如何一方面支持癌症的发展和干性,另一方面促进免疫反应。鉴于甲羟戊酸代谢的这种双重性质,作为抗癌疗法的一部分来操纵这种代谢途径的策略需要仔细分析风险与益处。
Mevalonate metabolism provides cancer and immune cells with diverse products to ensure cell functionality. Similar metabolic reprogramming that raises mevalonate metabolism to higher levels appears to drive both, epithelial mesenchymal transition (EMT) of cancer cells, a reverse differentiation program that generates cancer cells with stem cell properties, and immune cell training for increased responsiveness to secondary stimulation. In this review, we address how mevalonate metabolism supports cancer development and stemness on the one hand, and on the other promotes immune responsiveness. In view of this dual nature of mevalonate metabolism, strategies to manipulate this metabolic pathway as part of anti-cancer therapies require careful analysis of risks versus benefits.
DOI: 10.1101/gad.1061803
发表时间: 2003-05-15
影响因子: 10.5
作者:
Dontu, G;Abdallah, WM;Wicha, MS
通讯作者: Wicha, MS
肝癌的发生需要通过 CD44 增强的生长因子信号传导抑制 p53
DOI: 10.1016/j.ccell.2018.05.003
发表时间: 2018-06-11
期刊: Cancer cell
影响因子: 50.3
作者:
Dhar D;Antonucci L;Nakagawa H;Kim JY;Glitzner E;Caruso S;Shalapour S;Yang L;Valasek MA;Lee S;Minnich K;Seki E;Tuckermann J;Sibilia M;Zucman-Rossi J;Karin M
通讯作者: Karin M
DOI: 10.1200/jco.2002.06.037
发表时间: 2002-09-01
影响因子: 45.3
作者:
Berenson, JR;Hillner, BE;Biermann, JS
通讯作者: Biermann, JS
DOI: 10.1016/j.cell.2017.11.025
发表时间: 2018-01-11
期刊: CELL
影响因子: 64.5
作者:
Bekkering, Siroon;Arts, Rob J. W.;Netea, Mihai G.
通讯作者: Netea, Mihai G.
DOI: 10.1038/nri3198
发表时间: 2012-04-20
期刊: Nature reviews. Immunology
影响因子: --
作者:
通讯作者: --